Palisade Bio PALI 深 沪
等待开盘 09-08 09:30:00 美东时间
2.09
+0.045
+2.20%
华盛通- 最 高2.12
- 今 开2.03
- 成交量 175.53万股
- 最 低 2.00
- 昨 收 2.045
- 总市值 3.64亿
- 52周最高 2.855
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 0.5465
- 委 比 -55.10%
- 总股本 1.74亿
- 历史最高 18405.00
- 量 比 1.36
- 振 幅 5.87%
- 历史最低 0.53
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palisade Bio to Participate in Upcoming Investor Conferences
Palisade Bio, a clinical-stage biopharmaceutical company, announced its management will participate in three healthcare investor conferences in September 2026: the Wells Fargo Healthcare Conference in Boston, the Morgan Stanley Global Healthcare Conference in New York, and the H.C. Wainwright Global Investment Conference in New York. The company will host fireside chats and investor meetings, with live webcasts available on its website. Palisade ...
09-03 13:00
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The company reported $500.000 thousand in sales this quarter.
08-11 05:05
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
Palisade Bio jumps following Oppenheimer outperform initiation
Oppenheimer has initiated Palisade Bio (PALI) at outperforming, sending the stock ~14% higher in Thursday morning trading. The investment bank has an $8 price target (321% upside based on July 22 clos...
07-23 23:13
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8
Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.
07-23 18:57
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio, Inc. announced that its CEO, JD Finley, and President & Chief Medical Officer, Dr. Mitchell Jones, will participate in the Leerink Partners Therapeutics Forum in Boston on July 14-15. They will meet with institutional investors to discuss the company's clinical strategy, progress with PALI-2108, and upcoming milestones in its inflammatory bowel disease programs. Palisade Bio is advancing a next-generation oral PDE4 inhibitor prodrug...
07-10 13:00
分析师解读医疗健康企业：Evommune, Inc.（EVMN）与Palisade Bio（PALI）
医疗保健领域近期出现看涨信号，两家生物科技公司获分析师给出买入评级。 Evommune Inc.（EVMN）相关关键信息： 摩根士丹利维持买入评级，目标价2...
06-30 19:18
Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients With Active Ulcerative Colitis
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027 IND clearance marks a major developmen...
06-29 20:36
Palisade Bio Shareholders Approve Charter Amendments, Governance Matters
Palisade Bio ( ($PALI) ) just unveiled an announcement. At its annual meeting o...
06-12 06:53
Palisade Bio To Present Novel PDE4 Inhibitor Strategy For Fibrostenotic Crohn's Disease At NYAS Fibrosis Symposium
Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approachDenver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI)
06-09 20:46
